Nulibry

Drug Sentynl Therapeutics, Inc.
Total Payments
$578,412
Transactions
46
Doctors
4
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $234,759 21 4
2023 $237,678 17 0
2022 $105,975 8 0

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $566,275 32 97.9%
Travel and Lodging $12,058 10 2.1%
Food and Beverage $78.85 4 0.0%

Top Doctors Receiving Payments for Nulibry

Doctor Specialty Location Total Records
Liza Squires Chester Springs, PA $578,333 42
, MD Clinical Genetics (M.D.) West Palm Beach, FL $44.95 1
Kuntal Sen Student in an Organized Health Care Education/Training Program Atlanta, GA $22.22 1
, MD Neurology with Special Qualifications in Child Neurology Rockland, DE $6.01 1
, M.D Neurology with Special Qualifications in Child Neurology Washington, DC $5.67 1

About Nulibry

Nulibry is a drug associated with $578,412 in payments to 4 healthcare providers, recorded across 46 transactions in the CMS Open Payments database. The primary manufacturer is Sentynl Therapeutics, Inc..

Payment data is available from 2022 to 2024. In 2024, $234,759 was paid across 21 transactions to 4 doctors.

The most common payment nature for Nulibry is "Consulting Fee" ($566,275, 97.9% of total).